1. [Effective cetuximab monotherapy for a case of recurrence rectal cancer after multiple previous chemotherapy treatment (FOLFOX, FOLFIRI)].
- Author
-
Tomita M, Kuboi K, Kameyama N, Mitsuhashi H, Matsumoto N, Hasegawa Y, and Sekimoto Y
- Subjects
- Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Camptothecin analogs & derivatives, Camptothecin therapeutic use, Cetuximab, Fluorouracil therapeutic use, Humans, Leucovorin therapeutic use, Liver Neoplasms drug therapy, Liver Neoplasms secondary, Male, Middle Aged, Organoplatinum Compounds therapeutic use, Rectal Neoplasms pathology, Recurrence, Antibodies, Monoclonal therapeutic use, Drug Resistance, Neoplasm drug effects, Rectal Neoplasms drug therapy, Salvage Therapy
- Abstract
Cetuximab is an agent approved as epidermal growth factor receptor (EGFR)-positive for unresectable advanced or recurrent colorectal cancer. A 58-year-old man with liver metastasis had relapsed after resection of rectal cancer. We treated him with cetuximab monotherapy as third-line chemotherapy after treatment failures with infusional 5-FU, LV and oxaliplatin (FOLFOX4 regi- men); and infusional 5-FU, LV and irinotecan(FOLFIRI regimen). The patient was administered cetuximab (400 mg/m² initial dose and 250 mg/m²/ week thereafter). After sixteen weeks of treatment, a computed tomography scan revealed reduced sizes of the liver metastases. The tumor response has still been maintained after thirty courses of treatment, and the chemotherapeutic response was evaluated as a partial response according to the Response Evaluation Criteria In Solid Tumor guidelines. The main toxicity was a grade 2 rash, but was manageable by topical steroid and moisturizing agent. We have added some review of the literature, and the cetuximab therapy is reported.
- Published
- 2011